AstraZeneca’s (AZN) Sell Rating Reiterated at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “sell” rating restated by stock analysts at Deutsche Bank Aktiengesellschaft in a research report issued on Tuesday,Digital Look reports. They currently have a £115 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective would indicate a potential downside of 11.93% from the stock’s current price.

Other equities analysts have also issued reports about the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a £180 price objective on shares of AstraZeneca in a research note on Friday, June 26th. Citigroup upped their target price on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a report on Tuesday. Finally, Berenberg Bank reissued a “buy” rating and set a £160 target price on shares of AstraZeneca in a research report on Tuesday. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of £153.

AstraZeneca Trading Up 1.3%

Shares of LON AZN traded up GBX 170 during trading on Tuesday, reaching £130.58. The company had a trading volume of 31,164,986 shares, compared to its average volume of 30,378,725. The company’s fifty day moving average price is £134.89 and its 200-day moving average price is £140.60. AstraZeneca has a 12 month low of £107.44 and a 12 month high of £157.32. The stock has a market cap of £202.51 billion, a P/E ratio of 19.67, a PEG ratio of 0.86 and a beta of 0.23. The company has a quick ratio of 0.59, a current ratio of 0.91 and a debt-to-equity ratio of 71.66.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.